Fulcrum Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Fulcrum Therapeutics es Alex Sapir , nombrado en Jul 2023, tiene una permanencia de 1.33 años. compensación anual total es $7.36M, compuesta por 5% salario y 95% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.36% de las acciones de la empresa, por valor de $581.04K. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 7.8 años, respectivamente.
Información clave
Alex Sapir
Chief Executive Officer (CEO)
US$7.4m
Compensación total
| Porcentaje del salario del CEO | 5.0% |
| Permanencia del CEO | 1.3yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 2yrs |
| Promedio de permanencia en la Junta Directiva | 7.8yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
Nov 08
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Sep 13Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Sep 12Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Jul 12Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
Nov 17We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Aug 11Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Jul 11Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Jul 05Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Jun 27These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
May 10Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
Sep 03Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results
Aug 12News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
Aug 11Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$99m |
| Dec 31 2023 | US$7m | US$369k | -US$97m |
Compensación vs. Mercado: La compensación total de Alex($USD7.36M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.46M).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Alex con los resultados de la empresa.
CEO
Alex Sapir (57 yo)
1.3yrs
Permanencia
US$7,360,015
Compensación
Mr. Alexander C. Sapir, also known as Alex, serves as Chief Executive Officer, President and Director at Fulcrum Therapeutics, Inc. since July 01, 2023. Mr. Sapir has been Director at PhaseBio Pharmaceutic...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$7.36m | 0.36% $ 581.0k | |
| Chief Financial Officer | 1.3yrs | US$2.15m | 0% $ 0 | |
| Senior VP | 4yrs | US$2.32m | 0.018% $ 29.2k | |
| Executive Vice President of Patient Experience | 1.1yrs | US$2.19m | 0.012% $ 20.1k | |
| Founder | no data | sin datos | sin datos | |
| Founder | no data | sin datos | sin datos | |
| Founder | no data | sin datos | sin datos | |
| Founder | no data | sin datos | sin datos | |
| Founder | no data | sin datos | sin datos | |
| Controller & Principal Accounting Officer | 2.7yrs | sin datos | 0.018% $ 29.9k | |
| Chief Scientific Officer | 2yrs | sin datos | sin datos | |
| Chief People Officer | 4yrs | sin datos | sin datos |
2.0yrs
Permanencia media
60.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de FULC se considera experimentado (2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$7.36m | 0.36% $ 581.0k | |
| Independent Director | 8.3yrs | US$131.90k | 0.17% $ 272.6k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 7.8yrs | US$123.31k | 0.044% $ 70.8k | |
| Independent Director | 4.8yrs | US$136.40k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Director | 8.3yrs | US$724.50k | 0.93% $ 1.5m | |
| Independent Director | 7.9yrs | US$131.40k | 0.054% $ 86.9k | |
| Independent Chair of the Board | 6.4yrs | US$157.90k | 0% $ 0 | |
| Member of FSHD Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of FSHD Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of FSHD Clinical Advisory Board | no data | sin datos | sin datos |
7.8yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de FULC se considera experimentada (7.8 años de antigüedad promedio).